ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Daiichi Sankyo Announces Positive Top-line Results from Phase 3 Clinical Trial Evaluating Mirogabali
September 01, 2017Daiichi Sankyo announced positive top-line results from REDUCER (an Asian, phase 3, multicenter, RandomizEd, Double-blind, placebo-controlled 14-week stUdy of mirogabalin in patients with diabetiC pEripheral neuRopathic pain, followed by a 52-week open-la
Pharma Sources Insight January 2025
